Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18434957 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL7738031 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL12872570 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL15043900 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL1593467 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL20162037 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL1154515 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL1154638 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL20888696 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL12872828 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7PREPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | claimed |
| EP-3598974-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | Boehringer Ingelheim International GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3150204-A2 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | Boehringer Ingelheim International GmbH (DE) | 2017-04-05 | — | — | EP | disclosed |
| EP-3124041-A1 | DIABETES THERAPY | Boehringer Ingelheim International GmbH (DE) | 2017-02-01 | — | — | EP | disclosed |
| EP-1799639-B1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2013-09-04 | — | — | EP | disclosed |